You’ve probably heard from the financial planning gurus about all the money you could save if you stop drinking that £5 latte every day for a year (it’s about £1,800 if you don’t want to do the maths…). But what if you REALLY want that latte, maybe even feel you NEED that latte to get you through the day? Maybe you shop around a bit and find an equivalent cup of coffee for, say, £1.50. That’s a pretty sharp saving each year (again, with the math... about £1,250).
Perhaps it’s not such a leap to transition this comparison to the world of Pharmaceuticals. Not much more than a year ago, 3M partnered with Mylan to develop the first therapeutic equivalent alternative to GlaxoSmithKline’s Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla™ (salmeterol xinafoate/fluticasone propionate) in the UK. From the launch of Sirdupla™ through to Dec 2016 the National Health Service (NHS) has saved over £9 million1, and it can further save up to £35 million2 per year, assuming 80% of qualifying patients taking similar drug formulations via pMDI are prescribed Sirdupla™. We’re well beyond lattes now! And, what’s even more wonderful about this news is that it’s given patients suffering from asthma easy and affordable access to the care they need!
However, Sirdupla™ is not available in all the same strengths as Seretide®. It is only indicated in adults 18 years of age and older for the regular treatment of asthma where the use of a combination product (long-acting b2 agonist and inhaled corticosteroid) is appropriate. Sirdupla™ should not be used for patients with mild asthma. Only the Aerochamber Plus® spacer device should be used with Sirdupla™.
We’ve made it sound easy here, but the six-year process of developing a generic equivalent to a current marketed pMDI product was far from simple – requiring a dedicated team of inhalation experts successfully managing immense technical and operational challenges on an ongoing basis. This required a total system approach for the product to be efficacious, robust and reliable during patient use and during the product shelf life, as well as to meet regulatory and quality standards.
The partnership continues the proud tradition of firsts in inhalation for 3M, as we have combined our inhalation expertise with Mylan’s leadership in the global generics market. This strong partnership between Mylan and 3M to develop a successful generic product shows 3M Drug Delivery Systems Division is qualified to bring new solutions to a complex market.